Related references
Note: Only part of the references are listed.Targeted delivery of doxorubicin by magnetic mesoporous silica nanoparticles armed with mucin-1 aptamer
Paniz Siminzar et al.
JOURNAL OF DRUG TARGETING (2020)
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Omer Adir et al.
ADVANCED MATERIALS (2020)
Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics
Fangli Gao et al.
BIOMATERIALS (2020)
Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis
Liuwan Zhao et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles
Candace M. Day et al.
MOLECULES (2020)
Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment
Atefeh Yassemi et al.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY (2020)
Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells
Gamal-Eldein Fathy Abd-Ellatef et al.
PHARMACEUTICS (2020)
Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer
Saurav Bhattacharya et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Engineering peptide -targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy
Baksun Kim et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Ce6/Mn2+-chelated polydopamine@black-TiO2 nanoprobes for enhanced synergistic phototherapy and magnetic resonance imaging in 4T1 breast cancer
Yang Gao et al.
NANOSCALE (2020)
Nanoparticles: Properties, applications and toxicities
Ibrahim Khan et al.
ARABIAN JOURNAL OF CHEMISTRY (2019)
Redox-responsive hyaluronic acid nanogels for hyperthermia-assisted chemotherapy to overcome multidrug resistance
Bangbang Li et al.
CARBOHYDRATE POLYMERS (2019)
A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
Lu Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Bioinspired magnetic nanoparticles as multimodal photoacoustic, photothermal and photomechanical contrast agents
Zeid A. Nima et al.
SCIENTIFIC REPORTS (2019)
The role of photodynamic therapy on multidrug resistant breast cancer
Eric Chekwube Aniogo et al.
CANCER CELL INTERNATIONAL (2019)
Comprehensive Evaluation of Degradable and Cost-Effective Plasmonic Nanoshells for Localized Photothermolysis of Cancer Cells
Deepak S. Chauhan et al.
LANGMUIR (2019)
Checkpoint blockade and nanosonosensitizer- augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice
Wenwen Yue et al.
NATURE COMMUNICATIONS (2019)
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models
Walid S. Kamoun et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer
Parichart Naruphontjirakul et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Gold nanocluster-loaded hybrid albumin nanoparticles with fluorescence-based optical visualization and photothermal conversion for tumor detection/ablation
Sanghyun Park et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Toni Nunes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
Marialuisa Piccolo et al.
SCIENTIFIC REPORTS (2019)
A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer
Xin Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation
Tao Duan et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation
Neelam Poonia et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2019)
Pathways to Endocrine Therapy Resistance in Breast Cancer
Md Moquitul Haque et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging
Xiaoxue Xie et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Construction and in vitro and in vivo evaluation of folic acid-modified nanostructured lipid carriers loaded with paclitaxel and chlorin e6
Qibo Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
A dual-targeted hyaluronic acid-gold nanorod platform with triple-stimuli responsiveness for photodynamic/photothermal therapy of breast cancer
Weijun Xu et al.
ACTA BIOMATERIALIA (2019)
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
Malgorzata Szostakowska et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
Sohita Dhillon
CLINICAL DRUG INVESTIGATION (2019)
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
Fabio Barra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells
Tatiane Cristofolini et al.
Materials Science & Engineering C-Materials for Biological Applications (2019)
Improved tumor targeting and penetration by a dual-functional poly(amidoamine) dendrimer for the therapy of triple-negative breast cancer
Changliang Liu et al.
JOURNAL OF MATERIALS CHEMISTRY B (2019)
Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy
Yandan Yao et al.
JOURNAL OF MATERIALS CHEMISTRY B (2019)
Current issues regarding artificial intelligence in cancer and health care. Implications for medical physicists and biomedical engineers
Loredana G. Marcu et al.
HEALTH AND TECHNOLOGY (2019)
Assessing the Potential of Chitosan/Polylactide Nanoparticles for Delivery of Therapeutics for Triple-Negative Breast Cancer Treatment
S'Dravious DeVeaux et al.
REGENERATIVE ENGINEERING AND TRANSLATIONAL MEDICINE (2019)
Artificial intelligence in nanomedicine
Dean Ho et al.
NANOSCALE HORIZONS (2019)
Drug resistance and combating drug resistance in cancer
Xuan Wang et al.
CANCER DRUG RESISTANCE (2019)
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Afsane Bahrami et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Trastuzumab-modified DM1-loaded nanoparticles for HER2(+) breast cancer treatment: an in vitro and in vivo study
Ling Rong et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies
Venkata Talluri Siddhartha et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles
Guorui Jin et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
47OPhase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
M Pegram et al.
ANNALS OF ONCOLOGY (2018)
Investigation of an antitumor drug-delivery system based on anti-HER2 antibody-conjugated BSA nanoparticles
Nan Zhang et al.
ANTI-CANCER DRUGS (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
PAMAM-modified citric acid-coated magnetic nanoparticles as pH sensitive biocompatible carrier against human breast cancer cells
Hamed Nosrati et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2018)
Aptamer based assay of plated-derived grow factor in unprocessed human plasma sample and MCF-7 breast cancer cell lysates using gold nanoparticle supported alpha-cyclodextrin
Mohammad Hasanzadeh et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Yeon Hee Park et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
Xin Li et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
Lina Liu et al.
MOLECULAR THERAPY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
Adam M. Brufsky et al.
ONCOLOGIST (2018)
Antitumor effects of carbon nanotube-drug complex against human breast cancer cells
Shiping Yu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2018)
Multimodal selenium nanoshell-capped Au@mSiO2 nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer
Thiruganesh Ramasamy et al.
NPG ASIA MATERIALS (2018)
Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy
Najla M. Salkho et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Recent Advances in the Treatment of Breast Cancer
Christy W. S. Tong et al.
FRONTIERS IN ONCOLOGY (2018)
Cascaded Aptamers-Governed Multistage Drug-Delivery System Based on Biodegradable Envelope-Type Nanovehicle for Targeted Therapy of HER2-Overexpressing Breast Cancer
Tingxizi Liang et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells
Manoj B. Parmar et al.
BIOMACROMOLECULES (2018)
TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
Shaveta Vinayak et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
Jiayu Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Erika Paige Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nanoparticles as carriers for drug delivery in cancer
Ankita Dadwal et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects
Adil M. Allahverdiyev et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
Haixia Chen et al.
FRONTIERS IN PHARMACOLOGY (2018)
Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer
Mohammad Kamalabadi-Farahani et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer
Maryann Kwa et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Actively Targeted Deep Tissue Imaging and Photothermal-Chemo Therapy of Breast Cancer by Antibody-Functionalized Drug-Loaded X-Ray-Responsive Bismuth Sulfide@Mesoporous Silica Core-Shell Nanoparticles
Lihua Li et al.
ADVANCED FUNCTIONAL MATERIALS (2018)
Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics
Sayoni Ray et al.
THERANOSTICS (2018)
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
L. L. da Motta et al.
ONCOGENE (2017)
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin et al.
EUROPEAN JOURNAL OF CANCER (2017)
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
Gulden Menderes et al.
GYNECOLOGIC ONCOLOGY (2017)
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Hanxiao Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells
Brenda Brenner S. Cerqueira et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models
Chunlei Guo et al.
THERANOSTICS (2017)
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Ami N. Shah et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer
Dah-Shyong Yu et al.
UROLOGICAL SCIENCE (2017)
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
Dorota Kwapisz
BREAST CANCER RESEARCH AND TREATMENT (2017)
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies
Adam M. Brufsky
CANCER TREATMENT REVIEWS (2017)
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients
Carlo Palmieri et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Stacy L. Moulder et al.
CLINICAL CANCER RESEARCH (2017)
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
Thilo Gambichler et al.
BMC CANCER (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model
Xiang Huang et al.
IMMUNOLOGIC RESEARCH (2016)
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation
Gopal Venkatesh Shavi et al.
JOURNAL OF LIPOSOME RESEARCH (2016)
A new application of plant virus nanoparticles as drug delivery in breast cancer
Neda Esfandiari et al.
TUMOR BIOLOGY (2016)
Antibody drug conjugates: lessons from 20 years of clinical experience
A. W. Tolcher
ANNALS OF ONCOLOGY (2016)
RANK-RANKL signalling in cancer
Nathalie Renema et al.
BIOSCIENCE REPORTS (2016)
Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
Hirofumi Mukai et al.
CANCER SCIENCE (2016)
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
Kari B. Wisinski et al.
CLINICAL CANCER RESEARCH (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer
Michael A. Bruckman et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Specific targeting and noninvasive imaging of breast cancer stem cells using single-walled carbon nanotubes as novel multimodality nanoprobes
Achraf Al Faraj et al.
NANOMEDICINE (2016)
Development and Characterization of the Paclitaxel loaded Riboflavin and Thiamine Conjugated Carbon Nanotubes for Cancer Treatment
Swati Singh et al.
PHARMACEUTICAL RESEARCH (2016)
Therapeutic siRNA for drug-resistant HER2-positive breast cancer
Shenda Gu et al.
ONCOTARGET (2016)
Induction of intrinsic apoptotic pathway and cell cycle arrest via baicalein loaded iron oxide nanoparticles as a competent nano-mediated system for triple negative breast cancer therapy
Krishnamoorthy Kavithaa et al.
RSC ADVANCES (2016)
A stimuli-responsive Janus peptide dendron-drug conjugate as a safe and nanoscale drug delivery vehicle for breast cancer therapy
Ning Li et al.
JOURNAL OF MATERIALS CHEMISTRY B (2016)
Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo
Jie Meng et al.
SCIENTIFIC REPORTS (2016)
Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer
Hitesh Kulhari et al.
SCIENTIFIC REPORTS (2016)
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
Jessica R. McCombs et al.
AAPS JOURNAL (2015)
Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer
Worapol Ngamcherdtrakul et al.
ADVANCED FUNCTIONAL MATERIALS (2015)
Structure-Switching Aptamer Triggering Hybridization Chain Reaction on the Cell Surface for Activatable Theranostics
Yu-Min Wang et al.
ANALYTICAL CHEMISTRY (2015)
Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review
Demba Diedhiou et al.
ANNALES D ENDOCRINOLOGIE (2015)
Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer
Tingjie Yin et al.
BIOMATERIALS (2015)
Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Carlos Acevedo-Gadea et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
Milton Seiler et al.
CLINICAL BREAST CANCER (2015)
Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model
Gopal Venkatesh Shavi et al.
LIFE SCIENCES (2015)
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M. C. van der Lee et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Co-delivery of doxorubicin hydrochloride and verapamil hydrochloride by pH-sensitive polymersomes for the reversal of multidrug resistance
Nuannuan Li et al.
RSC ADVANCES (2015)
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Tomas Reinert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
PI3K/AKT signaling pathway and cancer: an updated review
Miriam Martini et al.
ANNALS OF MEDICINE (2014)
Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
Y. Homma et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers
Arindam Paul et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Jiri Polivka et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Suppression of BRCA1 sensitizes cells to proteasome inhibitors
Y. Gu et al.
CELL DEATH & DISEASE (2014)
Inorganic Nanovehicle Targets Tumor in an Orthotopic Breast Cancer Model
Goeun Choi et al.
SCIENTIFIC REPORTS (2014)
Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer
Jie-Yao Li et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer
Michael E. Werner et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Mario Roselli et al.
ONCOIMMUNOLOGY (2013)
Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
Reina Haque et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
Connie Jackaman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Brian M. Slomovitz et al.
CLINICAL CANCER RESEARCH (2012)
Heterogeneity in breast cancer
Kornelia Polyak
JOURNAL OF CLINICAL INVESTIGATION (2011)
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
Ilaria Grazia Zizzari et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Proteasome inhibitors in cancer therapy
Lisa J. Crawford et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
N. Berrada et al.
ANNALS OF ONCOLOGY (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
April A. N. Rose et al.
CLINICAL CANCER RESEARCH (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dynamic Assessment of Mitoxantrone Resistance and Modulation of Multidrug Resistance by Valspodar (PSC833) in Multidrug Resistance Human Cancer Cells
Fei Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Tumor necrosis factor and cancer, buddies or foes?
Xia Wang et al.
ACTA PHARMACOLOGICA SINICA (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
Ryan J. O. Dowling et al.
CANCER RESEARCH (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini
Eva Gonzalez-Suarez et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Share Paper
